Market Overview

Recent Patent Ruling A Positive For Pfizer

Share:
Recent Patent Ruling A Positive For Pfizer

A Federal District Court in Massachusetts recently issued a patent ruling that is "favorable" for Pfizer Inc. (NYSE: PFE), according to Gregg Gilbert of Deutsche Bank.

As noted by Gilbert, the District Court ruled in favor of Pfizer and Celltrion and said that Johnson & Johnson (NYSE: JNJ)'s patent for Remicade, a multi-billion-dollar product, is invalid. Johnson & Johnson's patent will now lapse in 2018.

Johnson & Johnson plans on appealing the ruling, but Pfizer continues to prepare for a launch of its equivalent (biosimilar) to Remicade in 2016. The analyst expects the biosimilar to drive sales of $360 million in 2016 and $662 million in 2017, "which includes OUS Inflectra (biosimilar infliximab), Nivestim (biosimilar filgrastim) and Retacrit (biosimilar epoetin zeta), and potential new launches in the US starting in 4Q16."

Related Link: The Least Popular Stocks This 13F Season

Gilbert added that Remicade saw sales of $1.2 billion in the second quarter, which implies full-year sales of roughly $5 billion. The analyst suggested that under a hypothetical scenario in which Pfizer's product is the only biosimilar on the market with a 40 percent operating margin, it could contribute $0.05 per share to Pfizer's earnings per share. Even if Pfizer were to sell its product at a 30 percent discount to Remicade and command a 30 percent market share, Pfizer's potential "may be significant."

Gilbert maintains a Buy rating on Pfizer's stock with an unchanged $44 price target.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for PFE

DateFirmActionFromTo
Feb 2020MizuhoInitiates Coverage OnBuy
Jan 2020RBC CapitalInitiates Coverage OnOutperform
Oct 2019Bank of AmericaReinstatesNeutral

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Reiteration Legal Analyst Ratings Best of Benzinga

 

Related Articles (JNJ + PFE)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ARDSRoth CapitalInitiates Coverage On18.0
PTCBairdAssumes
MNPRBrookline CapitalInitiates Coverage On42.0
HCKTCraig-HallumUpgrades
HNPDaiwa CapitalDowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com